Estrogen receptor a (ERa) is a ligand-inducible transcription factor that acts to regulate gene expression by binding to palindromic DNA sequence, known as the estrogen response element, in promoters of estrogen-regulated genes. In breast cancer ERa plays a central role, where estrogen-regulated gene expression leads to tumor initiation, growth and survival. As an approach to silencing estrogenregulated genes, we have studied the activities of a fusion protein between ERa and the promyelocytic leukemia zincfinger (PLZF) protein, a transcriptional repressor that acts through chromatin remodeling. To do this, we have developed lines from the estrogen-responsive MCF-7 breast cancer cell line in which the expression of the fusion protein PLZF-ERa is conditionally regulated by tetracycline and shows that these feature long-term silencing of the expression of several well-characterized estrogen-regulated genes, namely pS2, cathepsin-D and the progesterone receptor. However, the estrogen-regulated growth of these cells is not inhibited unless PLZF-ERa expression is induced, an observation that we have confirmed both in vitro and in vivo. Taken together, these results show that PLZF-ERa is a potent repressor of estrogen-regulated gene expression and could be useful in distinguishing estrogen-regulated genes required for the growth of breast cancer cells. Gene Therapy (2005) 12, 452-460.
Introduction
Breast cancer is the most common cancer afflicting women in industrialized countries and is second only to lung cancer in cancer deaths. 1 Estrogens stimulate the growth of the majority of breast cancers, and endocrine therapies are aimed at limiting local and systemic estrogen biosynthesis and, with the use of antiestrogens, which have contributed significantly to recent decreases in breast cancer mortality.
2, 3 However, in a substantial proportion of patients, resistance to these agents eventually arises and therefore there is a need to identify new approaches, such as gene therapy, for the treatment of resistant breast cancer and for the identification of novel therapeutic targets.
Estrogen actions are mediated by two receptors (estrogen receptor a (ERa) and estrogen receptor b (ERb)) that are members of the nuclear receptor (NR) superfamily of ligand-activated transcription factors, 4 which regulate the expression of estrogen-responsive genes upon binding estrogen. Estrogens and antiestrogens bind to the ligand-binding domain (LBD). Transcription activation by ERa is mediated by a ligandactivated transcription activation function, AF-2 located within the LBD and by transcription activation function AF-1 encoded within the N-terminal 180 amino acids. 5 Activation of gene expression requires the recruitment of RNA polymerase II and the general transcription factors to gene promoters. However, the eukaryotic genome is packaged into chromatin based on the nucleosome unit in which 147 bp of DNA is wrapped around an octamer of core histones comprised of histones H2A, H2B, H3 and H4, with nucleosomes separated by 10-60 bp of linker DNA. 6 The N-terminal 'tails' of the core histones are believed to project out of the nucleosome and to interact with linker DNA and DNA in adjacent nucleosomes, to provide nucleosome compaction that is repressive for transcription. These histone tails are subject to extensive post-translational modifications, including lysine acetylation, lysine and arginine methylation and serine phosphorylation. 7, 8 Some of these modifications have been shown to stimulate gene expression, presumably through the modulation of DNA/histone contacts and/or the recruitment of other chromatin-interacting proteins. For example, acetylation of histone H3 and H4 tails at lysines often stimulates gene expression. Moreover, the recent identification of enzymes that acetylate core histones, histone acetyltransferases (HATs), and the finding that HATs are recruited to gene promoters by interaction with transcription factors, has led to the realization that transcription factors activate gene expression, at least in part, by facilitating histone acetylation. 9, 10 For example, upon ligand binding NR recruit the CBP/p300 and P/ CAF HAT complexes through direct interaction and/or by the recruitment of the CBP/p300 interacting p160 'coactivators' SRC-1/NCoA-1, TIF2/GRIP1/NCoA-2 and pCIP/ACTR/AIB1. 11, 12 In the case of ERa, estrogen binding stimulates histone H4 acetylation of estrogenregulated genes through the action of CBP/p300. 13 Hypoacetylation of core histones is often correlated with transcriptional silencing and many transcription factors recruit histone deacetylase (HDAC) complexes. Repression of E2F-activated genes by the retinoblastoma (Rb) protein is mediated, at least in part, by the recruitment of HDAC complexes by Rb. The adenoviral E1A protein prevents Rb repression of gene expression, in part, by blocking its association with HDAC.
14 Similarly, gene repression by Mad/Max and unliganded NR is mediated by the recruitment of the Sin3A HDAC complex. 11 Several transcriptional repressor proteins including MeCP2, which binds to methylated cytosines in CpG islands, have also been demonstrated to recruit HDAC. 15, 16 Collectively, these data indicate that histone acetylation/deacetylation is critical in the regulation of gene expression by transcription factors, as well as providing a powerful mechanism for epigenetic silencing of gene expression. Indeed, recent studies indicating that histone deacetylation plays an important role in X-chromosome inactivation support this contention, 17 while a link with DNA methylation has been demonstrated by the finding that some HDAC complexes contain DNA methyltransferases. [18] [19] [20] [21] One important role for chromatin remodeling proteins in human disease has been highlighted by certain chromosomal translocations that feature in acute myeloid leukemias. Examples of such translocations are the t(8;16) translocation that fuses the MOZ and CBP HATs 22 and the inv(8)(p11q13) chromosomal rearrangement that fuses MOZ with TIF2/GRIP1/NCoA-2. 23 Many other translocations feature transcription activators fused to transcriptional repressor proteins. For example, the t(11;17) translocation in acute promyelocytic leukemia (APL) fuses the promyelocytic leukemia zinc-finger (PLZF) transcription repressor gene with the retinoic acid receptor a gene (RARa). 24 The resulting PLZF-RARa fusion protein recruits the Sin3A HDAC complex through interaction of PLZF with the corepressors N-CoR, SMRT, [25] [26] [27] [28] as well as through direct interactions with Sin3A and HDAC1. 29 These interactions result in histone hypoacetylation and potent silencing of retinoic acid-regulated genes.
We hypothesized that by creating a fusion protein between the DNA-binding domain (DBD) of ERa and either an HDAC or another component of HDAC complexes, it may be possible to achieve strong transcriptional silencing of estrogen-regulated genes by causing and maintaining the promoters of estrogenregulated genes in a deacetylated state. As RARa is related to ERa and since PLZF-RARa silences expression of retinoic acid-regulated genes through recruitment of the Sin3A HDAC complex by PLZF, we decided to investigate the potential of this strategy by replacing the RARa portion of PLZF-RARa with homologous sequences from ERa. Such a strategy could facilitate the identification of estrogen-regulated genes, the stimulation of whose expression leads to breast cancer cell proliferation. We show that PLZF-ERa represses expression of estrogen-regulated gene expression, growth and tumor formation in nude mice by the estrogen-dependent breast cancer-derived MCF7 cell line.
Materials and methods

Plasmids
The expression vector pSG5 30 and its derivatives encoding human ERa (HEG0) and the deletion mutant lacking amino acids 1-180 (HEG19; ERa-DAF-1) or lacking amino acids 281-595 (ERa-DLBD) have previously been described, 31 as have the 17M-ERE-globin-CAT and pSGDlacZ reporter genes. 32 ERE-1-TATA-luciferase was a kind gift from Dr JH White. PLZF-ERa was generated by site-directed mutagenesis of pSG5-PLZF 24 to generate an XhoI site following sequences encoding amino acid 456 of PLZF. Sequences encoding amino acids 151-595 of ERa were cloned into the XhoI site following mutagenesis of HEG0, replacing amino acids 457-673 of PLZF. PLZF-ERa was isolated from pSG5-PLZF-ERa by digestion with BamHI/EcoRI and cloned into the NruI site in pRevTRE (Clontech, UK), following blunt ending. All constructs were verified by automated DNA sequencing.
Cell transfection, extract preparation, immunoblotting and gelshifts COS-1 cells were maintained in Dulbecco's modified Eagle's Medium (DMEM) (Gibco-BRL), supplemented with 5% fetal calf serum (FCS). Cells were plated in 9 cm dishes, 16-24 h prior to transfection by the calcium phosphate co-precipitation technique with 5 mg of each expression plasmid and 15 mg of human placental DNA (Sigma-Aldrich, UK) as the carrier. Precipitates were removed 16 h after transfection by washing in DMEM/ 5% FCS. After a further 44-48 h, the cells were harvested in chilled phosphate-buffered saline (PBS). Whole-cell extracts (WCE) were prepared and immunoblotted using monoclonal antibodies for ERa (B10, F3 33 ) or 6F11 (Novocastra, UK) and PLZF, 34 as described. 32 Gelshift assays were performed using estrogen response element (ERE) oligonucleotides and conditions, also as described. 32 WCE of MCF7 cells and derived cell lines were prepared and immunoblotting performed, also as described. 32 Luciferase, CAT and b-galactosidase assays COS-1 cells maintained as described above were split into 24-well plates in DMEM lacking phenol red and supplemented with 5% dextran-coated charcoal-treated FCS (DSS) 35 and transfected using lipofectamine 2000 (Invitrogen, UK) using 150 ng of ERE-1-TATA-luciferase and 100 ng of the renilla luciferase reference plasmid (RLTK; Promega, UK), together with 200 ng of expression plasmids, as appropriate. Bluescript M13+ (BSM; Promega, UK) was included as a carrier to a total of 900 ng of DNA. The medium was changed after 5 h, and 17b-estradiol (E2, 10 nM), 4-hydroxytamoxifen (OHT; 100 nM) or ICI 182,780 (ICI; 100 nM) were added, an equal volume Inhibiting estrogen responses in breast cancer cells L Buluwela et al of ethanol being added to the no ligand controls. Cells were harvested 16-20 h later. Lysates were prepared and assayed for firefly and renilla luciferase activities according to the manufacturer's instructions (Promega, UK).
MCF7-Tet-Off (MCF7-TO) and derived cell lines, split into six-well plates in DMEM lacking phenol red supplemented with 5% DSS, were transfected using the calcium phosphate method, with 1 mg of 17M-EREglobin-CAT, 125 ng of pSGDlacZ, and BSM to a total of 5 mg of DNA. E2 was added to cells 30 min after transfection. The precipitates were removed by washing cells 16 h after transfection and fresh E2 was added to the medium, as appropriate. After a further 48 h, the cells were harvested in 200 ml of 1 Â Reporter gene assay buffer (Roche, UK). b-galactosidase and CAT assays were performed using ELISA kits according to the manufacturer's protocols (Roche, UK).
Generation of MCF7-TO cells stably transfected with PLZF-ERa
MCF7-TO cells (BD Biosciences, UK) in DMEM supplemented with 10% FCS, containing 100 mg/ml G418 and 1 mg/ml of the more stable tetracycline analogue doxytetracycline (Tet), were transfected with pRevTRE-PLZFERa using Fugene6 (Roche, UK). After 16 h, the cells were washed and fresh medium containing G418 and Tet was added. Hygromycin B (80 mg/ml) was added after 24 h and resistant colonies were picked into fresh medium containing hygromycin B, G418 and Tet. The remaining hygromycin B-resistant colonies were pooled by trypsinization and passaged as a pool, as well as being grown individually to establish cell lines. The pool and derived lines were screened for PLZF-ERa expression by RT-PCR, immunofluorescence staining and immunoblot analysis.
Immunostaining MCF7-TO and derived cell lines were plated on sterile round glass coverslips in 24-well plates in medium containing 1 mg/ml Tet. Cells were washed after 24 h and fresh medium with or without Tet was added. For immunofluorescence, the cells were washed with chilled PBS, fixed in ice-cold 100% methanol for 10 min, washed three times for 5 min with PBS, blocked with 10% goat serum in PBS for 30 min and incubated with the PLZF monoclonal antibody in 0.1% goat serum/PBS for 1 h at room temperature. Following three washes with PBS and further blocking with 10% goat serum/PBS, the cells were incubated with FITC-conjugated goat antimouse immunoglobulins (Sigma, UK) for 1 h. After five washes with PBS, the coverslips were mounted onto glass microscope slides using Vectashield mountant containing Dapi nuclear stain (Vector Laboratories, UK). Slides were visualized using a Zeiss LS510 confocal microscope.
For immunohistochemical staining, cells were trypsinized and cytospun onto glass slides, followed by 10 min fixation in acetone and washing in water. Endogenous peroxidase activity was blocked with 2% solution of hydrogen peroxide in methanol for 10 min. Slides were again washed, followed by blocking with 10% horse serum (Serotec, UK) in Tris-buffered saline (TBS) for 10 min and incubation with a monoclonal progesterone receptor antibody (PR88; Menarini Diagnostics, UK), according to the supplier's protocols. Slides were washed with TBS and incubated with biotinylated horse anti-mouse immunoglobulins, followed by incubation with avidin-biotin complex and incubation with diaminobenzidine according to the manufacturer's protocols (Vector, UK).
RT-PCR analysis of gene expression
RT-PCR was carried out using primers for the progesterone receptor gene (PR; 5 0 -CCAGAGCCCACAATACAGCTTC-3 0 and 5 0 -GCCAGCCTGACAGCACTTTCTAAG-3 0 ). Control RT-PCR analysis for mRNA dosage was carried out for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 5 0 -CCACCCATGGCAAATTCCATGGCA-3 0 and 5 0 -TCTA GACGGCAGGTCAGGTCCAC-3 0 ). Real-time PCR was carried out according to the manufacturer's protocols on an Applied Biosystems 7700 Real-Time PCR system, using Assay-On-Demand primers for PR, pS2, cathepsin D and GAPDH.
Cell growth assays
MCF7-TO and PLZF-ERa clones were routinely cultured in DMEM supplemented with 10% FCS and containing G418, Tet and hygromycin B, as appropriate. For the growth assays, 5 Â 10 4 cells were seeded per well of sixwell plates in DMEM containing 10% FCS and G418. After 24 h, the cells were washed with PBS and DMEM lacking phenol red, supplemented with 5% DSS and G418. Cells were cultured for a further 48 h, at which time E2 (10 nM) and Tet (1 mg/ml) were added as appropriate. Ethanol was added to the no ligand controls. This time point was designated day 0. The media were changed every 72 h throughout the course of the experiment. Triplicate wells for each treatment were washed, cells trypsinized, stained using trypan blue and four cell counts were taken per well using a hemocytometer.
Tumorigenicity
In all, 32 female 8-to 10-week Balb/c nude mice (Harlan UK) were randomly divided into two groups. The mice received 0.72 mg 60-day release E2 pellets (Innovative Research of America, USA), subcutaneously implanted in one flank 24 h before injection of cells. A total of 16 mice were also implanted with 42 mg 60-day release Tet pellets. MCF7-TO-PLZF-ERa cells (line JP23), grown in medium containing Tet, were trypsinized and 5 Â 10 6 cells in 0.1 ml of PBS were subcutaneously injected into the other flank of each mouse and tumor volumes were measured every 3 days, according to the formula (tumor width squared Â tumor length)/2. Nude mice were killed after 60 days or when the diameter of the tumor reached 15 mm. Two-tailed Student's t-test was used to determine whether differences in tumor volume in the +/À Tet groups were statistically significant. The xenograft experiments were conducted after appropriate ethical approval and licensing was obtained in accordance with the UK 'Guidance on the operation of animals (Scientific Procedure) Act 1986' (HMSO, London, UK, 1990).
Inhibiting
PLZF-ERa inhibits the expression of an estrogen-regulated reporter gene
The PLZF-RARa fusion protein contains amino acids 1-456 of PLZF fused to sequences encoded within exons 4-10 of the RARa gene. The analogous ERa sequences encoding amino acids 151-595, which includes the DBD and LBD were cloned in frame with amino acids 1-456 of PLZF (Figure 1a) . The ability of PLZF-ERa to specifically bind to ERE was established by gelshift analysis of total lysates prepared from transient transfection of COS-1 cells (Figure 1b) . Immunoblotting with antibodies for ERa and PLZF showed the presence of a 100 kDa polypeptide, consistent with the predicted molecular weight of PLZF-ERa (Figure 1c) . We next examined the ability of PLZF-ERa to inhibit the activity of an estrogenregulated firefly luciferase reporter gene in COS-1 cells.
In contrast with ERa, PLZF and PLZF-ERa failed to stimulate reporter gene activity (Figure 1d ). However, PLZF-ERa, but not PLZF, almost completely inhibited the ERa stimulation of reporter gene activity, indicating that the inhibition requires the ERa sequences present in PLZF-ERa.
Owing to a lack of ERa activity in the absence of ligand, however, it was not clear whether PLZF-ERa inhibits E2-regulated genes in the absence of ligand or if the repressive activity of PLZF-ERa requires estrogen binding by PLZF-ERa. As ERa-DLBD lacks the LBD, it activates the expression of E2-regulated genes similarly in the presence or absence of E2, through the activity of AF-1. Therefore, cotransfection of PLZF-ERa with ERa-DLBD was used to determine whether PLZF-ERa inhibits reporter gene activity in the absence of ligand as well as in its presence (Figure 1e 
growth. Therefore, we used an MCF7 cell line stably expressing the tetracycline repressor-VP16 (TetR-VP16) fusion protein (MCF7-TO; BD Biosciences, UK), in which expression of the gene of interest is prevented in the presence of tetracycline, being activated upon its removal. pRevTRE-PLZF-ERa was transfected into MCF7-TO cells and stable lines were generated following selection in the presence of Hygromycin B. The lines so generated were scored for their ability to inhibit Inhibiting estrogen responses in breast cancer cells L Buluwela et al the activity of an E2-regulated CAT reporter gene in a Tet-dependent manner. Of 44 clones, 38 inhibited reporter gene activity in a Tet-regulated manner (data not shown). Of these, two clones were selected for further study simply on the basis of good repression of reporter gene activity (Figure 2a) . CAT activity was stimulated as expected in the parental MCF7-TO cells and the addition of Tet did not greatly affect reporter gene activity in these cells. In the PLZF-ERa pool and in clones JP13 and JP23, reporter activity was stimulated by E2 to an extent similar to that observed for MCF7-TO cells, when Tet was present in the medium. In the absence of Tet, however, CAT activity was reduced two-fold in the case of the pool, and was reduced to background levels in JP13 and JP23 cells. This difference in inhibition of reporter gene activity in the pool, compared to the clones, is presumably due to the fact that in the pool there will be cells that are hygromycin resistant but do not express PLZF-ERa, perhaps due to gene rearrangements following stable integration of DNA, as well as clones expressing PLZF-ERa at levels lower than those seen in the JP13 and JP23 lines.
In carrying out the reporter gene experiments, we noted that culturing the cells for less than 72 h in the absence of Tet gave little repression of reporter gene activity (data not shown; Figure 2a) . In order to determine whether this was due to the inducibility of PLZF-ERa expression in the stable lines, indirect immunofluorescence staining of JP23 cells at different times following removal of Tet from the medium was carried out. Immunofluorescence using the PLZF antibody revealed that there is little detectable PLZF-ERa 24 h after removal of Tet from the medium. Indeed, maximal numbers of PLZF-ERa-positive cells were only observed 96 h following removal of Tet (Figure 2b) .
Tet inducibility of PLZF-ERa expression was confirmed by immunoblotting of lysates prepared from the pool and selected stable lines. Removal of Tet led to considerable induction in PLZF-ERa expression in MCF7-TO Pool, JP13 and JP23, detectable with PLZF and the B10 antibody to ERa amino acids 150-165, sequences present in PLZF-ERa (Figure 2c ). As expected, PLZF-ERa expression was lower in the Pool, compared to JP13 and JP23, and was not detected in the parental MCF7-TO cells. Low-level PLZF-ERa expression was also evident in JP13 and JP23 in the presence of Tet. Immunoblotting with the 6F11 ERa antibody, which does not recognize PLZF-ERa, showed that ERa expression was similar in the presence or absence of Tet for each cell line, indicating that the apparent increase in ERa levels observed using the ERa B10 antibody are due to the migration of a degradation product of PLZF-ERa at the Inhibiting estrogen responses in breast cancer cells L Buluwela et al same molecular weight as ERa. These results suggest that PLZF-ERa levels in JP13 and JP23 are five-to 10-fold higher than levels of ERa. Finally, immunoblotting with antibody 6F11 also revealed that ERa levels are lower in JP13 and JP23, when compared to the parental cells or the pool.
PLZF-ERa inhibits the expression of estrogen-regulated genes in MCF7-TO cells
We next investigated whether PLZF-ERa can repress the expression of endogenous estrogen-regulated genes. The PR gene is a well-defined estrogen-regulated gene. 36, 37 RT-PCR analysis of RNA from MCF7-TO cells showed similar levels of PR expression in the presence or absence of Tet (Figure 3a) . PR expression was reduced in the pool and was almost completely abolished in JP13 and JP23 following Tet removal from the medium (Figure 3a) . Interestingly, PR expression was also lower in JP13 and JP23 in the presence of Tet, compared to PR levels in parental MCF7-TO cells. These findings were confirmed by real-time PCR. In MCF7-TO cells, PR levels were stimulated about eight-fold by 16 h treatment with E2 Inhibiting estrogen responses in breast cancer cells L Buluwela et al (Figure 3b, lanes 9 and 10) . In JP13 and JP23 cells, however, there was little detectable PR expression when Tet was absent and expression was only slightly higher in the presence of Tet, although it should be noted that in the presence of Tet the induction of PR expression by ER was similar to that seen in MCF7-TO cells (7.9-and 9.2-fold in JP13 and JP23, respectively) ( Figure 3b , lanes 1, 2, 5 and 6). Similarly, the fold induction by E2 in MCF7-TO, JP13 and JP23 in the presence of Tet for pS2 was 3.3-, 3.4-and 2.6-fold, respectively, while that for CTD was 2.1-, 1.3-and 1.8-fold, respectively. Immunocytochemical staining showed that PR protein was absent from JP13 and JP23 cells cultured in the presence of Tet and E2 (Figure 3c ), and PR was also undetectable by immunoblotting (Figure 3d ). Cathepsin D and pS2 were originally identified in screens for estrogen-regulated genes in breast cancer cell lines. [38] [39] [40] Real-time PCR analysis showed that pS2 and cathepsin D levels were reduced in the PLZF-ERa lines to levels below those found in MCF7-TO cells in the absence of ligand (Figure 3b ). This reduction was reflected in the near complete loss of detectable pS2 and cathepsin D protein by immunoblotting (Figure 3d) . Moreover, the reduction in pS2 and cathepsin D expression was largely independent of PLZF-ERa expression in these lines, as was also observed for PR.
PLZF-ERa inhibits the estrogen-dependent growth of MCF7-TO cells and tumor formation in nude mice
Growth assays were carried out to investigate the effect of PLZF-ERa expression on the estrogen-regulated growth of MCF7-TO cells. MCF7-TO, JP13 and JP23 cells were grown in the presence or absence of Tet and estrogen, as appropriate. As expected, MCF7-TO cells proliferated in the presence but not in the absence of E2, and their growth was independent of Tet ( Figure 4a) . Similarly, JP13 and JP23 cells proliferated in an E2-dependent manner when Tet was present in the medium (Figure 4b and c) . However, in the absence of Tet JP13 and JP23, cells did not proliferate, demonstrating that PLZF-ERa expression inhibits the E2-regulated growth of MCF7-TO cells.
MCF7 cells form tumors in nude mice if implanted together with slow-release estrogen pellets. In order to determine whether PLZF-ERa expression inhibits MCF7 tumors in nude mice, in addition to its growth inhibitory effects in culture, 60-day release E2 pellets were implanted into nude mice. The mice were divided into two groups, one of which was transplanted with MCF7-TO cells and the second group with JP23 cells. Six out of 11 mice injected with MCF7-TO cells developed tumors within 4 weeks of injection, whereas no tumors were obtained from nine mice injected with JP23 cells (data not shown), suggesting that PLZF-ERa expression inhibits tumor formation by MCF7 cells.
To demonstrate that the lack of tumors for JP23 cells is not due to loss of the ability of these cells to form tumors but rather to PLZF-ERa expression, slow-release E2 pellets were implanted into 32 mice. One-half of these mice were also implanted with slow-release Tet pellets. As observed in the initial experiment, cells transplanted without Tet did not exhibit tumor growth ( Figure 5) , with the exception of one xenograft, which on further analysis was shown to produce a tumor that no longer expressed PLZF-ERa and two other animals, which upon histological analysis appeared to have cysts at the site of cell implantation. In contrast, inhibition of PLZF-ERa expression by implanting a Tet pellet resulted in tumors in 12 out of 16 animals.
Discussion
Transcription activation by ERa requires the estrogendependent recruitment of transcriptional coactivators that remodel chromatin to facilitate gene expression. Antiestrogens such as tamoxifen inhibit ERa activity, at least in part, by facilitating the recruitment by ERa of the transcriptional corepressors NcoR/SMRT and the associated HDAC complexes. In order to obtain specific and potent repression of estrogen-regulated gene expression in breast cancer cells, we generated a chimeric ERa in which AF1 sequences were replaced by amino acids 1-456 of the transcriptional repressor PLZF. 24 PLZF was chosen as a fusion partner because it is a naturally found example of a transcriptional repressor fused to an NR that silences expression of retinoic acid-regulated genes through the recruitment of the NcoR/SMRT-Sin3A HDAC complex by PLZF. [25] [26] [27] [28] [29] PLZF-ERa might therefore be expected to repress in a manner similar to, or more efficaciously than tamoxifen, through the recruitment of HDAC complexes to promoters of estrogen-regulated genes.
As expected, PLZF-ERa bound to an ERE and repressed the activity of ERa in transient transfection experiments. Interestingly, repression by PLZF-ERa was ligand dependent. The activity of many proteins can be regulated in cis by fusion with the ERa LBD. It is possible that the ligand regulation seen here reflects a similar ligand-dependent regulation of PLZF activity. Alternatively, the ligand-regulated repression may reflect ligand requirement for DNA binding by PLZF-ERa. Indeed, many studies, most recently using chromatin immunoprecipitation, have show that ERa recruitment to promoters of estrogen-regulated genes is ligand-dependent, 13, 41, 42 indicating that in vivo, ERa recruitment to DNA requires ligand binding. This may also be the case for PLZF-ERa.
Several attempts at obtaining stable expression of PLZF-ERa in breast cancer cell lines that express ERa and whose growth is estrogen-regulated were unsuccessful, suggesting that PLZF-ERa expression inhibits the growth of these cells through silencing of estrogen-regulated gene expression. Therefore, we employed an MCF7 TetOff cell line in which expression of the gene of interest is induced upon removal of Tet from the medium. Characterization of stable lines demonstrated that PLZF-ERa expression was induced upon removal of Tet from the medium and the activity of a transiently transfected reporter gene was inhibited in the absence but not in the presence of Tet. The expression of the estrogen-regulated progesterone receptor, pS2 and cathepsin D genes was reduced to levels observed in the parental cells in the absence of estrogen. Unexpectedly, however, the expression of these genes was similarly reduced in these lines in the presence of Tet in the culture medium. The reasons for this are unclear, but may be due to the reduced levels of ERa in the cloned lines, or may reflect repression by the small amounts of PLZF-ERa expression evident in these lines in the presence of Tet.
Notwithstanding, the PLZF-ERa lines demonstrated estrogen regulation of their growth that was similar to that of MCF7-TO cells, whereas their growth was inhibited in the presence of estrogen when Tet was removed and PLZF-ERa expression was induced. Similarly, JP23 cells required Tet for tumor growth in vivo. Collectively, these data suggest that there are two classes of estrogen responses that can be distinguished in these lines. The first is exemplified by the regulation of progesterone receptor, pS2 and cathepsin D, which show potent, constitutive repression in these PLZF-ERa lines. The second class of response is exhibited as a result of overt expression of PLZF-ERa and causes the repression of estrogen-regulated growth. Therefore, these lines uniquely provide a system for dissecting the estrogen growth response from other estrogen-regulated pathways. In considering this, we have already observed that there are greatly reduced levels of the cell cycle regulatory proteins cyclin D1, p27 and p21 in the PLZF-ERa lines in this study (data not shown), suggesting that these estrogen-regulated genes are not candidates for this response.
Our findings indicate that it should be possible to use the MCF7-TO PLZF-ERa lines described in this paper to identify estrogen-regulated genes associated with growth, specifically by defining those genes that are repressed by PLZF-ERa but which show estrogen regulation in the absence of PLZF-ERa to levels similar to those seen in the parental MCF7-TO cells. Such investigations are clearly suited to bioinformatic approaches using gene expression microarray and proteomic analyses. Studies using such a strategy are underway and we find that it is possible to identify novel estrogenregulated genes associated with growth. Inhibiting estrogen responses in breast cancer cells L Buluwela et al
